Page 3 - Genentech Access Solutions News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs
04-Mar-2021
Genentech’s Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition
– Systemic sclerosis (SSc) is a rare disease that impacts up to 75,000 people in the United States –
– Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening –
– In a global study, Actemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placebo –
– The U.S. Food and Drug Administration previously granted Priority Review designation to Actemra for the treatment of SSc-ILD – ....

United States , South San Francisco , Levi Garraway , Karl Mahler , Loren Kalm , Shirley Dang , Roche Group , Drug Administration , Global Product Development , Genentech Access Solutions , Access Solutions , Priority Review , Global Product , Rodnan Skin Score , Prescribing Information , Boxed Warning , Medication Guide , Important Safety Information , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு சான் பிரான்சிஸ்கோ , லெவி க்யாரவ , கார்ல் மஹ்லர் , லோரன் கல் , ஷெர்லி டங் , ரோச் குழு , உலகளாவிய ப்ராடக்ட் வளர்ச்சி ,